Cambridge Healthtech Institute’s 2nd Annual

Oncolytic Virus Immunotherapy

Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant deals by Pfizer, Celgene, Amgen, BMS and Boehringer Ingelheim, however, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models. CHI’s Second Annual Oncolytic Virus Immunotherapy conference brings together the leading industry and academic leaders to discuss the critical steps driving oncolytic virotherapy forward.

Preliminary Agenda


Latest Updates and Future Directions in Oncolytic Virus Immunotherapy

KEYNOTE PRESENTATION: Engineering and Bio-Selection to Optimize an Oncolytic Virus Platform

John Bell, Ph.D., Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute


Improving the Targeting and Efficacy of Oncolytic Viruses

Tumor Selective HSV-Based Oncolytic Vectors for Treatment of GBM

Paola Grandi, Ph.D., Senior Research Director, Immunology/Virology, Oncorus, Inc.

WO-12, a Multi-Mechanistic Immuno-Oncolytic Therapy

Steve H. Thorne, CSO, Western Oncolytics Ltd.

PeptiCRAd, a Novel Oncolytic Virus-Based Therapeutic Cancer Vaccine

Sari Pesonen, Vice President, Clinical Development, Valo Therapeutics

Synthetic Virology: Redesigning Viruses for Cancer Therapy

Clodagh O'Shea, Ph.D., Associate Professor, Howard Hughes Medical Institute Faculty Scholar

Emerging Investigator: Development of OV Immunotherapy Using a Novel Preclinical GBM Model

Hiroshi Nakashima, Ph.D., Instructor, Neuroscience, Brigham and Women's Hospital


Oncolytics in Development: Update on Major Clinical and Preclinical Therapies

Long-Term Follow-Up in Recurrent High Grade Glioma Patients with Durable Responses Treated with Toca 511 and Toca FC

Asha Das, M.D., Vice President, Clinical Development and Medical Affairs, Tocagen

Talk Title to be Announced

Naomi DeSilva, Ph.D., Clinical Site Educator, Sillajen

A Clinical Update from Turnstone Biologics

Caroline Breitbach, Ph.D., Vice President, Translational Development, Turnstone Biologics

Development of an Attenuated Oncolytic Influenza A Virus Expressing Mycobacterial ESAT-6 Protein

Michael Bergmann, M.D., Ph.D., CMO, Vacthera


Oncolytics in an Era of Combination Therapies

Rationale for Using Oncolytic Viruses as the Backbone of Combination Immunotherapy Regimens

Howard Kaufman, M.D., FACS, Surgical Oncologist, Rutgers Cancer Institute of New Jersey

FEATURED PRESENTATION: Developing Tumor-Specific Immunogene (T-Sign) Combination Immunotherapies by Arming the Oncolytic Group B Adenovirus Enadenotucirev

Brian R. Champion, Ph.D., CSO, Psioxus Therapeutics Ltd.

T-Stealth Technology Promotes Synergy between Oncolytic Viruses and Immuno-Stimulatory Agents

Matthew Mulvey., Ph.D., CEO, BeneVir Biopharm, Inc.

What Does It Take to Cure Glioblastoma; Combinations Plus?

Samuel D. Rabkin, Ph.D., Professor, Neurosurgery, Massachusetts General Hospital and Harvard Medical School

Emerging Investigator: Oncolytic Virus Induced Rad51 Degradation: Synergy with Poly(Adp-Ribose) Polymerase Inhibitors in Treating Glioblastoma

Jianfang Ning, Ph.D., Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School




For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
781-247-6266
dbarry@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today